A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis

The goal of this investigator-initiated, real-world, observational study is to investigate the impact of weight loss on treatment efficacy in overweight or obese Chinese patients with moderate-to-severe plaque psoriasis.

The main question it aims to answer is:

Does a structured weight loss intervention (including dietary management, exercise, and/or pharmacotherapy) improve the clinical response to psoriasis therapy in this population, as measured by the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) score below 3 at Week 24?

Researchers will compare the Weight Loss Intervention Group (receiving standard psoriasis care plus a personalized weight management program) to the Control Group (receiving standard psoriasis care only) to see if the addition of weight loss strategies leads to superior improvements in psoriasis severity, metabolic parameters, and quality of life.

Participants will:

Receive standardized treatment for their psoriasis based on disease severity.

Be allocated (based on patient preference and clinical judgment) to either the intervention or control group.

In the intervention group, receive and follow a personalized weight management plan, which may include dietary counseling, a tailored exercise regimen, and/or Glucagon-Like Peptide-1（GLP-1） receptor agonist therapy (e.g., Semaglutide, Tirzepatide) if indicated.

Undergo scheduled assessments at baseline, Week 12, and Week 24, including:

Clinical evaluations (PASI, Physician's Global Assessment, body surface area).

Anthropometric measurements (weight, BMI, waist/hip circumference).

Quality of life assessment (Dermatology Life Quality Index).

Safety monitoring for adverse events. To investigate the impact of weight loss on treatment efficacy among overweight/obese Chinese patients with plaque psoriasis.

Study Overview

• Status: Not yet recruiting
• Conditions: Psoriasis
• Intervention / Treatment: Combination product: Weight loss and psoriasis treatment; Combination product: psoriasis treatment

• Study Type: Observational
• Enrollment (Estimated): 70

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Clinical diagnosis of plaque psoriasis and Body Mass Index (BMI) categorized as overweight or obese.

Description

Inclusion Criteria:

1. Age ≥ 18 years, regardless of gender.
2. Having signed the informed consent form.
3. Clinical diagnosis of plaque psoriasis.
4. Body Mass Index (BMI) categorized as overweight or obese.
5. For female patients: No plans for pregnancy or oocyte donation during the study period and voluntary use of highly effective physical contraception.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Individuals deemed by the investigator to be unsuitable for participation in this study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Weight Loss Group; receiving standard psoriasis care plus a personalized weight management program	Combination product: Weight loss and psoriasis treatment; In the weight loss group, receive standardized treatment for their psoriasis based on disease severity and follow a personalized weight management plan, which may include dietary counseling, a tailored exercise regimen, and/or GLP-1 receptor agonist therapy (e.g., Semaglutide, Tirzepatide) if indicated.
Control Group; receiving standard psoriasis care only	Combination product: psoriasis treatment; Receive standardized treatment for their psoriasis based on disease severity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of PASI<3 at Week 24	Proportion of patients undergoing weight loss treatment who achieve a Psoriasis Area and Severity Index (PASI) score below 3 at Week 24.	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of PASI<3 at Week 12	Proportion of patients undergoing weight loss treatment who achieve a PASI score below 3 at Week 12.	Week 12
Changes of BMI	Changes from baseline in Body Mass Index (BMI) at Week 12 and Week 24 in patients undergoing weight loss treatment.	Week 12 and Week 24
Proportion of PGA 0/1 (Physician's Global Assessment)	Proportion of patients undergoing weight loss treatment who achieve a Physician's Global Assessment (PGA) score of 0 or 1 at Week 12 and Week 24.	Week 12 and Week 24
Proportion of DLQI<6	Proportion of patients undergoing weight loss treatment who achieve a Dermatology Life Quality Index (DLQI) score below 6 at Week 12 and Week 24	Week 12 and Week 24

Collaborators and Investigators

• Sponsor: Peking University Third Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): January 28, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: January 20, 2026
• First Submitted That Met QC Criteria: January 28, 2026
• First Posted (Actual): February 2, 2026

Study Record Updates

• Last Update Posted (Actual): February 2, 2026
• Last Update Submitted That Met QC Criteria: January 28, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Psoriasis
• Other Study ID Numbers: M20260001